Geron (STU:GON) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:GON Geron Corp STU:GON
45 GF Score
Price €1.24
GF Value €5.86
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Geron FFO?

FFO (Funds from operations) only applies to REITs.

STU:GON
45GF Score
Geron Corp STU:GON
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Geron (STU:GON) Overvalued in 2026?

Based on GuruFocus' analysis, Geron stock appears to be undervalued. The current stock price of €1.24 is trading 78.8% below its estimated GF Value™ of €5.86. GuruFocus considers Geron to be Possible Value Trap.

Key valuation signals for STU:GON:

  • FFO:
  • GF Value™: €5.86 vs. price of €1.24 (78.8% below fair value)
  • GF Score™: 45/100 with 4 warning signs

No single metric tells the full story. See the STU:GON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Geron Business Description

Other Exchanges GERN:USA1GERN:Italy0IV3:UK
Address 919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
45GF Score

Get the complete analysis for STU:GON

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.24
Price
€5.86
GF Value